Clinical trial
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in…
NCT00354146 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00354146 |
|---|---|
| Title | A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia. |
| Official title | A Phase 2 Study Evaluating the Efficacy of the Farnesyl Transferase Inhibitor (FTI) R115777 in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML) |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Nonlymphocytic, Acute |
| Intervention type | Drug |
| Interventions | tipifarnib (R115777) |
| Enrollment | 252 |
| Start date | Apr 1, 2001 |
| Completion | Jul 1, 2003 |
| First posted | Jul 20, 2006 |
| Last update posted | Feb 1, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: